Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.5 USD | +1.21% | +11.11% | +7.30% |
04-04 | Transcript : VYNE Therapeutics Inc. - Special Call | |
02-29 | VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 10
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Domzalski
CEO | Chief Executive Officer | 58 | 20-02-29 |
Tyler Zeronda
DFI | Director of Finance/CFO | 38 | - |
Iain Stuart
CTO | Chief Tech/Sci/R&D Officer | 51 | 20-02-29 |
Mutya Harsch
LAW | General Counsel | 50 | 20-02-29 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Pat LePore
BRD | Director/Board Member | 69 | 20-09-09 |
Steven Basta
BRD | Director/Board Member | 59 | 14-12-31 |
Anthony Bruno
BRD | Director/Board Member | 68 | 20-02-29 |
Director/Board Member | 62 | 19-02-28 | |
David Domzalski
CEO | Chief Executive Officer | 58 | 20-02-29 |
Director/Board Member | - | 12-31 | |
Sharon Barbari
BRD | Director/Board Member | 70 | 20-02-29 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 14,098,888 | 12,874,235 ( 91.31 %) | 0 | 91.31 % |
Company contact information
VYNE Therapeutics, Inc.
685 Route 202/206 North Suite 301
08807, Bridgewater
+
http://www.vynetherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.30% | 35.25M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- VYNE Stock
- Company VYNE Therapeutics Inc.